Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-021-00867-8
Abstract: Screening for activating driver gene alterations at the time of diagnosis is the standard of care for advanced non-small cell lung cancer (NSCLC). Activating RET fusions are identified in approximately 1–2% of NSCLCs and have… read more here.
Keywords: ret fusion; cell lung; non small; fusion positive ... See more keywords
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.09.037
Abstract: BACKGROUND Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined.… read more here.
Keywords: patients ret; ret fusion; cancer; therapy ... See more keywords
Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2017.08.019
Abstract: OBJECTIVES RET fusions have been reported in 1-2% of lung adenocarcinomas, and represent an actionable target. Patients whose tumors possess RET fusion are associated with clinical benefit from the treatment with multi-kinase inhibitors such as… read more here.
Keywords: novel kif13a; kif13a ret; ret fusion; cancer ... See more keywords
Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2093190
Abstract: ABSTRACT Introduction Selpercatinib is a RET selective tyrosine kinase inhibitor with nanomolar potency against diverse RET alterations, including fusions, activating point mutations, and acquired resistance mutations. Rearranged during transfection (RET) gene is a validated target… read more here.
Keywords: non small; selpercatinib ret; fusion positive; small cell ... See more keywords
Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001483
Abstract: Immune ch eckpoint inhibitors (ICIs) represent a milestone in advanced nonsmall cell lung cancer (NSCLC). Nevertheless, NSCLC with known oncogenic drivers has been overlooked in most studies evaluating anti-programmed death-1/programmed death ligand 1. Rearranged during… read more here.
Keywords: lung cancer; fusion; ret fusion; cell lung ... See more keywords
Selpercatinib monotherapy in a Chinese patient with RET fusion/EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001527
Abstract: Rearranged during transfection (RET) fusions and epidermal growth factor receptor (EGFR) mutations are potent oncogenic drivers in patients with nonsmall cell lung cancer (NSCLC), but rarely co-exist. Concurrent RET/EGFR mutations have been reported in patients… read more here.
Keywords: egfr mutated; lung; ret fusion; egfr ... See more keywords
Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-17-0008
Abstract: Oncogenic rearrangements in RET are present in 1%–2% of lung adenocarcinoma patients. Ponatinib is a multi-kinase inhibitor with low-nanomolar potency against the RET kinase domain. Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in… read more here.
Keywords: pr2; ret fusion; inhibition; ret inhibition ... See more keywords
Abstract CT011: Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct011
Abstract: Introduction: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor, is approved in multiple countries for the treatment of RET fusion-positive lung or thyroid cancers. RET fusions are also implicated in the pathogenesis of… read more here.
Keywords: fusion positive; thyroid cancers; non; ret fusion ... See more keywords
Abstract 4007: Efficacy of vepafestinib in preclinical models of RET fusion-driven sarcoma models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4007
Abstract: Background: Vepafestinib (TAS0953/HM06, Vepa) is a 2nd generation RET-selective inhibitor that effectively penetrates the brain, and inhibits the wildtype RET kinase domain (KD) and RET KD mutants (G810, V804, Y806, L730) (presented at AACR-NCI-EROTC 2021… read more here.
Keywords: hmsc ret; efficacy; ret fusion; preclinical models ... See more keywords
Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221105020
Abstract: Introduction: Oncogenic alterations in RET occur in 1–2% of non-small-cell lung cancers (NSCLCs). The efficacy and safety of the first-in-class, highly selective, and potent RET inhibitor selpercatinib in Chinese patients with RET fusion-positive NSCLC remains… read more here.
Keywords: safety; fusion positive; efficacy; ret fusion ... See more keywords
Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3584
Abstract: 3584Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ no... read more here.
Keywords: selpercatinib loxo; ret fusion; loxo 292; 292 patients ... See more keywords